Skip to main content
Make a Gift

Sickle Cell Disease Research

The UNC Comprehensive Sickle Cell Program provides cutting edge treatment to patients of all ages with sickle cell disease.  A vital component of a comprehensive program is clinical research, and we are able to offer our patient population the opportunity to participate in clinical research studies, both industry-sponsored and investigator-initiated.  Two medications, crizanlizumab and voxelotor, and a gene therapy have received FDA approval for the treatment of sickle cell due in part to our patient’s willingness to participate in clinical research.

For more information about Sickle Cell Disease research, please visit: SCD Research

Active Enrolling Studies

 

  1. An Open-label, Expanded Access Protocol for Pediatric Patients with Sickle Cell Disease Who Have No Alternative Treatment Options

  2. Identifying barriers to pediatric to adult transition in Sickle Cell Disease using two data collection tools via telehealth vs in-person

  3. Sickle Cell Disease (SCD) Biochip: Towards a Simple and Reliable Way to Monitor Sickle Cell Disease

  4. Achieving Understanding of the Natural history of sickle cell Trait (AUNT)

  5. A Prospective Study to Evaluate the Disease Status in Patients with Sickle Cell Disease: A Globin Regional Data and Discovery (GRNDaD) Network

  6. Implementing the Infusion Clinic Model In Sickle Cell Disease

  7. Improving the Implementation of Cardiac Screening in Sickle Cell Disease

  8. Low Oxygen in Pregnant Women with Sickle Cell Disease

  9. A pilot study assessing p16 levels in patients with sickle cell disease at UNC

  10. Hydroxyurea Pharmacokinetics and Pharmacodynamics in Adults with Sickle Cell Anemia

  11. Red Blood Cell Survival Study: The Impact of Oxidative Stress on Erythocyte Biology

  12. An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (Hibiscus)

  13. A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease

  14. An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial

  15. A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)

  16. An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease

  17. BMT CTN 1507: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

  18. Sickle cell Transplant Evaluation of Long term and LAte-effects Registry (STELLAR)